|
Cladribine (trade names Leustatin, Litak and Movectro) is a medication used to treat hairy cell leukemia (HCL, leukemic reticuloendotheliosis) and multiple sclerosis. Its chemical name is 2-chlorodeoxyadenosine (2CDA). As a purine analog, it is a synthetic anti-cancer agent that also suppresses the immune system. Chemically, it mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, which interferes with the cell's ability to process DNA. It is easily destroyed by normal cells except for blood cells, with the result that it produces relatively few side effects and results in very little non-target cell loss. ==Medical uses== Cladribine is used for the treatment of symptomatic hairy cell leukemia. According to the drug's FDA-approved prescribing information, the median time to normalization of blood counts in people with hairy cell leukemia is: two weeks for platelets, five weeks for absolute neutrophil counts, eight weeks for hemoglobin, and nine weeks for a patient to have all three parameters normalized. Weeks are counted from the first day of treatment, and all patients were on a seven-day daily treatment schedule for these studies. It is under investigation for other B cell leukemias and lymphomas, such as mantle cell lymphoma,〔(Mantle Cell Lymphoma initiative )〕 and for use in the treatment of multiple sclerosis. According to the Histiocytosis Association, cladribine is used to treat histiocytosis.〔(Histiocytosis Association )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cladribine」の詳細全文を読む スポンサード リンク
|